Regenxbio (RGNX) Presents Additional Positive Interim Data from Phase I/II Trial of RGX-121 for Treatment of MPS II at ASGCT

May 14, 2021 7:06 AM EDT

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

  • RGX-121, a one-time gene therapy for MPS II, continues to be well-tolerated with no drug-related serious adverse events
  • Biomarkers and measures of neurodevelopmental function from patients in Cohorts 1 and 2 continue to indicate CNS activity following RGX-121 administration
  • Evidence of systemic enzyme expression and biomarker activity continues to be observed
  • REGENXBIO recently initiated dosing of patients in Cohort 3

REGENXBIO Inc. (Nasdaq: RGNX) today announced a safety update and additional positive interim data from the ongoing Phase I/II trial of RGX-121 for the treatment of patients up to 5 years old diagnosed with Mucopolysaccharidosis Type II (MPS II), also known as Hunter Syndrome. The latest data from this trial will be presented today at the American Society of Gene and Cell Therapy (ASGCT) 24th Annual Meeting by Dr. Roberto Giugliani, Professor, Department of Genetics, UFRGS, Medical Genetics Service, HCPA, Porto Alegre, Brazil.

"I am pleased to report additional data from the Phase I/II trial of RGX-121 in patients with MPS II. The biomarker data from these patients continues to demonstrate that the I2S enzyme is active in the CNS and importantly, continued cognitive development has been observed in the majority of patients who have been followed for more than 6 months. In addition, emerging evidence of systemic enzyme expression and activity has been shown in urine and plasma, including in patients who are naive to enzyme replacement therapy, the current standard of care," said Dr. Giugliani. "The potential to provide therapeutic benefit from a one-time gene therapy would be a meaningful advancement for the treatment of MPS II patients."

"It is encouraging to see continued efficacy signals up to two years after administration of RGX-121 in our Phase I/II trial. The safety profile we have seen to date, combined with evidence of CNS and systemic effects, are encouraging as we seek to bring a one-time gene therapy treatment to the MPS II community," said Steve Pakola, M.D., Chief Medical Officer of REGENXBIO. "We have begun dosing patients in Cohort 3, and we look forward to providing further program updates later this year."

RGX-121 is an investigational one-time gene therapy designed to deliver the gene that encodes the iduronate-2-sulfatase (I2S) enzyme using the AAV9 vector. RGX-121 is administered directly to the central nervous system (CNS). Patients in Cohorts 1 and 2 received doses of RGX-121 at 1.3x1010 genome copies per gram (GC/g) of brain mass and 6.5x1010 GC/g of brain mass, respectively. REGENXBIO began dosing patients in Cohort 3 at an increased dose of 2.0x1011 GC/g of brain mass. As of April 25, 2021, RGX-121 is reported to be well-tolerated with no drug-related serious adverse events (SAEs) in nine patients dosed with RGX-121 in Cohorts 1-3.

Data Summary and Safety Update from Cohort 1 and 2

Time of post-administration follow-up for patients in Cohorts 1 and 2 ranges from 24 weeks to two years. Five patients have completed the 48-week immunosuppression regimen, per study protocol. Six of the patients were receiving weekly, intravenous enzyme replacement therapy (ERT) at the time of enrollment; two of these patients have since discontinued ERT.

CSF Biomarker Data from Cohort 1 and 2

Biomarker data from patients in Cohorts 1 and 2 indicate encouraging signals of I2S enzyme activity in the CNS following one-time administration of RGX-121. Heparan sulfate (HS) levels are a key biomarker of I2S enzyme activity and the patients in Cohorts 1 and 2 demonstrated decreased HS in the cerebrospinal fluid (CSF) up to 2 years following RGX-121 administration. Combined median reductions from baseline were 30.3% at Week 8 and 35.0% at the last timepoint available for each patient. Similarly, these patients demonstrated decreased levels of D2S6, a component of HS, up to 2 years following RGX-121 administration, with median reductions from baseline of 44.1% at Week 8 and 40.4% at the last timepoint available for each patient. In addition, I2S enzyme concentration in the CSF, which was undetectable in all patients prior to dosing, was measurable in all five patients from Cohort 2 after RGX-121 administration.

Neurocognitive Development Data from Cohort 1 and 2

Patients in Cohorts 1 and 2 also demonstrated continued neurocognitive development up to two years after RGX-121 administration. Five patients have assessments of neurodevelopment function at timepoints beyond 6 months, and of those patients, four have continued to demonstrate neurocognitive development, according to the Bayley Scales1. One patient entered the study with significant delay in neurocognitive development at baseline but has demonstrated relative stabilization following RGX-121 administration and has continued to acquire expressive and receptive language skills based on the Bayley Scales.

Systemic Biomarker Data and Clinical Efficacy

Patients in Cohorts 1 and 2 demonstrated evidence of I2S enzyme activity in urine following administration of RGX-121. Notably, two patients in Cohort 2 who were naive to ERT demonstrated rapid reductions in urine total glycosaminoglycans (GAG) levels of over 50% at the latest timepoint available following RGX-121 administration. Two patients in Cohort 1 discontinued ERT over one year after administration of RGX-121, and the total urine GAG levels following ERT withdrawal remained relatively consistent with total urine GAG levels prior to ERT withdrawal. Total urine GAG levels decreased among four patients who continue to receive ERT following administration of RGX-121. Patients in both cohorts demonstrated increases in I2S protein concentration levels in plasma over time following administration of RGX-121.

The study findings are available at

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, FDA

Related Entities

Definitive Agreement, FDA